Strategic Shift: Novo Nordisk Partners with Former Legal Rival to Defend Market Position

Novo Nordisk ends patent fight with Hims & Hers in a distribution deal for Wegovy and Ozempic, as pricing pressure and Eli Lilly competition reshape the market.

In a surprising strategic reversal, Danish pharmaceutical giant Novo Nordisk has transformed a bitter patent dispute into a commercial alliance. The company, which was engaged in a legal battle with telehealth provider Hims & Hers as recently as February, has now entered into a distribution partnership with its former adversary. This move is a direct response to intense pricing pressure and mounting competition from Eli Lilly in the lucrative market for weight-loss injections.

A Partnership Forged from Conflict

The agreement resolves pressing issues for both entities. Hims & Hers will cease selling unregulated, copycat weight-loss compounds, thereby alleviating regulatory pressure from the U.S. Food and Drug Administration (FDA). In return, the platform will begin offering Novo Nordisk's authentic Wegovy and Ozempic medications.

For Novo Nordisk, this collaboration is a business imperative. Market analysts suggest that rival Eli Lilly could seize market leadership in the coming years. Consequently, securing every additional distribution channel is crucial for maintaining sales volume and protecting market share.

Financial Headwinds and a Strategic Pivot

The competitive landscape and new U.S. government pricing regulations are squeezing profitability. The company's financial forecast for 2026 reflects this strain, projecting a decline in both revenue and earnings of between 5% and 13%.

Under the leadership of new CEO Mike Doustdar, management is pursuing an aggressive pricing strategy to broaden patient access. The Wegovy pill, slated for U.S. launch in January 2026, is priced at $149—significantly below the injectable version. While this enhances affordability, it simultaneously pressures short-term income. The stock's performance mirrors these challenges, having lost approximately 55% of its value over the past year and currently trading well below its 200-day moving average.

Wall Street Recalibrates Expectations

A lowered financial outlook and setbacks in clinical research have prompted several major financial institutions to reassess their stance on Novo Nordisk:

• Deutsche Bank: Downgraded the stock to "Hold" with a price target of 275 DKK, following disappointing trial data for the hopeful drug CagriSema in a head-to-head comparison with Eli Lilly's treatment.
• J.P. Morgan: Highlighted the looming threat of lost exclusivity rights but noted that the ongoing share buyback program, valued at over 15 billion DKK, provides financial support.
• Morgan Stanley: Now views the risk-reward profile as balanced following the substantial share price depreciation in recent months.

Long-Term Diversification Efforts

To reduce dependence on its injectable portfolio, Novo Nordisk is undertaking a significant operational overhaul. The firm is investing 430 million euros in an Irish facility dedicated to producing Wegovy tablets. Simultaneously, it has moved to diversify its pipeline through the $4.7 billion acquisition of Akero Therapeutics, gaining access to new treatments for liver disease.

While these long-term initiatives develop, the successful market penetration of the Wegovy pill through partners like Hims & Hers remains the critical lever for operational stabilization in the current year.